Trillium Therapeutics, Inc.
(NASDAQ CM: TRIL)
Rigrodsky Law, P.A. is investigating Trillium Therapeutics, Inc. (“Trillium”) regarding possible breaches of fiduciary duties and other violations of law related to Trillium’s agreement to be acquired by Pfizer, Inc. Under the terms of the agreement, Trillium’s shareholders will receive $18.50 in cash for each share of Trillium common stock they own.